Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Blood Neoplasia · 2026 · PMC12997325 · PMID 41859348

Europe PMC DOI

hedged sentences

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

a nonsignificant trendP = .071so close (0.05 < p ≤ 0.1)

Stratified by treatment, patients with CK/MK receiving IC showed a nonsignificant trend toward improved survival vs inv(3)/t(3;3) receiving IC (mOS: 12 months [95% CI, 9.0-22] vs 10 months [95% CI, 5.6-35]; P = .071) ( Figure 5 B).

also in 3,449 other papers

a favorable trendno p-value reported

In contrast, NRAS mutations were linked to improved survival (HR, 0.60; 95% CI, 0.39-0.94; P = .027), whereas IDH1 (HR, 0.58; 95% CI, 0.31-1.09; P = .092) and IDH2 (HR, 0.56; 95% CI, 0.30-1.02; P = .057) mutations showed a favorable trend nearing significance.

also in 993 other papers

nearing significanceno p-value reported

In contrast, NRAS mutations were linked to improved survival (HR, 0.60; 95% CI, 0.39-0.94; P = .027), whereas IDH1 (HR, 0.58; 95% CI, 0.31-1.09; P = .092) and IDH2 (HR, 0.56; 95% CI, 0.30-1.02; P = .057) mutations showed a favorable trend nearing significance.

also in 148 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.